A 2014 study found that CTS participants who only used estrogen therapy (ET) had lower lung cancer mortality. Researchers did not find any association between CTS participants’ use of estrogen plus progestin therapy use and lung cancer mortality. Read more here.
Among CTS participants, use of hormone therapy (HT) has not associated with risk of developing lung cancer. Read more here.
A study of six large cohorts, including the CTS, found that the incidence of lung cancer among never smokers age 40 to 79 years in these six cohorts ranged from 14.4 to 20.8 per 100,000 person-years in women and 4.8 to 13.7 per 100,000 person-years in men. Read more here.